Board member gets 5,750 RSUs at Rigel Pharmaceuticals (RIGL)
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units of common stock at no cost. These units will be acquired upon vesting and are scheduled to fully vest on the date prior to the company’s next annual meeting, subject to his continued service on the board. Following this equity award, Frohlich beneficially owns 7,000 shares of Rigel’s common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Frohlich Mark W
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 5,750 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 7,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 5,750 units
Grant price: $0.00 per share
Shares owned after grant: 7,000 shares
3 metrics
RSU grant size
5,750 units
Restricted stock units of common stock granted to director
Grant price
$0.00 per share
Equity award granted as compensation, not purchased for cash
Shares owned after grant
7,000 shares
Total common stock beneficially owned following the award
Key Terms
Restricted Stock Unit, Annual Meeting, Board of Directors
3 terms
Restricted Stock Unit financial
"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Annual Meeting financial
"The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
Board of Directors financial
"subject to the Reporting Person's continuous service on the Company's Board of Directors."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
What did Rigel Pharmaceuticals (RIGL) disclose about Mark W. Frohlich in this Form 4?
Rigel Pharmaceuticals reported that director Mark W. Frohlich received 5,750 restricted stock units of common stock as an equity award. These units vest in full before the next annual meeting, increasing his beneficial ownership to 7,000 shares, all held directly.
When will Mark W. Frohlich’s 5,750 Rigel (RIGL) RSUs vest?
The restricted stock units are scheduled to fully vest on the date prior to Rigel Pharmaceuticals’ next annual meeting. Vesting is conditioned on Frohlich’s continuous service on the company’s board of directors through that time, according to the Form 4 footnote.
Is Mark W. Frohlich’s Rigel (RIGL) transaction a market buy or a compensation grant?
The transaction is a compensation grant, not a market purchase. The Form 4 uses code “A” and notes 5,750 restricted stock units awarded at $0.00 per share, to be acquired upon vesting rather than through an open-market buy or sale.